Meet the Expert: AAV Suspension Platform Generation with significant Increase in Viral Vector Titer and Yield

Wednesday, January 27, 2021 - 14:50 to 15:10
Advanced Therapies Connect 2021 - Phacilitate's 2nd Virtual Experience - WATCH


The field of gene therapy has experienced significant growth in recent years. Adenoassociated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that increased viral vector titer and yield on our platform.
The advancements in the platform include:
  • Significant increase of viral vector titer
  • Increased coverage of AAV serotypes
  • Decreased process variability by using chemically defined growth medium
  • Optimized and simplified downstream processing
  • An increase in integrated testing capacity.

Related Information


Yiyu Dong
Head of Cell Line Development - WuXi Advanced Therapies (WuXi ATU)
David Barnard
Senior Scientist, Process and Technology Development - WuXi Advanced Therapies (WuXi ATU)
< Back